Milestone Pharmaceuticals Inc. Net Income Loss

• Milestone Pharmaceuticals Inc. showed a decrease of -51.9% in Net Income Loss from 2024 to 2025.
• This data is from Milestone Pharmaceuticals Inc.'s annual report (Form 10-K), filed with the SEC on March 20, 2026.
• XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 8 years of available data (2018 to 2025), Milestone Pharmaceuticals Inc.'s Net Income Loss has declined by 172.0%.
• Historical annual values: Fiscal year 2025: -$63.06 million | Fiscal year 2024: -$41.52 million | Fiscal year 2023: -$59.69 million | Fiscal year 2022: -$58.39 million | Fiscal year 2021: -$42.85 million | Fiscal year 2020: -$49.97 million | Fiscal year 2019: -$55.23 million | Fiscal year 2018: -$23.19 million.
• Data sourced from SEC EDGAR public filings as of June 21, 2026.

Last verified: June 21, 2026